Tillkännagivande • 5h

Alkermes Announces Interim Results From Long-Term Extension Study Of Alixorexton In Adults With Narcolepsy Type 1 And Type 2

Alkermes plc announced results from a planned interim analysis of the ongoing long-term extension (LTE) study evaluating alixorexton in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Across all dose groups in both NT1 and NT2 participants, alixorexton demonstrated sustained clinically meaningful improvement from baseline on the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) at week 24 of the LTE, approximately nine months after the first dose for participants treated with alixorexton in the randomized double-blind period of the Vibrance-1 and Vibrance-2 phase 2 studies. Alixorexton also demonstrated sustained and clinically meaningful improvement from baseline across patient-reported outcomes (PROs) evaluating cognition and fatigue at week 24. Alixorexton was generally safe and well tolerated at all doses tested. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, NT2 and idiopathic hypersomnia (IH). This ongoing open-label extension study is designed to evaluate the long-term safety, tolerability and durability of treatment effect of alixorexton. This interim analysis reflects safety and tolerability data as of the May 12, 2026 data cutoff and efficacy measures collected at week 24 of the LTE for participants who enrolled in the LTE after completing Vibrance-1 (NT1) or Vibrance-2 (NT2), reflecting treatment with alixorexton for up to nine months. The LTE remains ongoing and is open for enrollment for participants who complete ongoing phase 2 and phase 3 studies of alixorexton. In the Vibrance-1 phase 2 parent study, alixorexton demonstrated statistically significant and clinically meaningful improvements in wakefulness and cataplexy in participants with NT1 (n=92) randomized to receive a once-daily dose of alixorexton (4 mg, 6 mg or 8 mg) or placebo. Approximately 85% of Vibrance-1 participants (n=78) enrolled in the LTE. Dose adjustment was allowed during the first four weeks of the LTE, with most participants receiving 6 or 8 mg as their most frequent dose. As of the data cutoff, approximately 90% (n=70) of these participants remained on treatment. All alixorexton dose groups for NT1 achieved normative wakefulness on the MWT (mean sleep latency (MSL) =20 minutes) at week 24 of the LTE, with a mean observed MSL of approximately 29 minutes across LTE participants. Improvements in ESS from baseline were sustained in the normal range (a score of =10) for all doses tested throughout the LTE, with a mean observed ESS of 7.5 at week 24 across LTE participants. Alixorexton demonstrated improvements from baseline on weekly cataplexy rate (WCR) at all LTE assessment timepoints. At week 24, the median WCR across LTE participants was 2. Improvements from baseline in exploratory PROs evaluating cognition and fatigue were generally maintained across dose groups in the LTE. At week 24, most NT1 participants across all doses had cognitive functioning scores within the normal range, as measured by the British Columbia – Cognitive Complaints Inventory (BC-CCI), and mean fatigue scores were within the normal range, as measured by PROMIS-Fatigue, across all doses. Prior to treatment with alixorexton in the parent study, participants reported mean scores of moderate cognitive impairment and fatigue. Alixorexton was generally safe and well tolerated across all doses tested in the LTE. No serious treatment-emergent adverse events (TEAEs) were reported. Most TEAEs were mild to moderate in severity. The most common TEAEs in the LTE were headache, micturition urgency, pollakiuria, and nasopharyngitis. In the Vibrance-2 phase 2 parent study, alixorexton demonstrated statistically significant and clinically meaningful improvements in wakefulness in participants with NT2 (n=93) randomized to receive a once-daily dose of alixorexton (10 mg, 14 mg or 18 mg) or placebo. Approximately 70% of Vibrance-2 participants (n=63) enrolled in the LTE. Dose adjustment was allowed during the first four weeks of the LTE, with most participants receiving 14 or 18 mg as their most frequent dose. As of the data cutoff, approximately 80% (n=51) of these participants remained on treatment. All alixorexton dose groups for NT2 demonstrated further improvement on the MWT at week 24 of the LTE, with mean observed MSL of approximately 18 minutes across LTE participants. Improvements in ESS were sustained in the normal range (a score of =10) for the 14 mg and 18 mg dose groups throughout the LTE. Across LTE participants, the mean observed ESS was 8.9 at week 24. Improvements from baseline in exploratory PROs evaluating cognition and fatigue were generally maintained in NT2 participants across dose groups in the LTE. At week 24, most NT2 participants across all doses had cognitive functioning scores within the normal or mild range, as measured by the BC-CCI, and mean fatigue scores were within the normal range, as measured by PROMIS-Fatigue, across all doses. Prior to treatment with alixorexton in the parent study, participants reported overall mean scores of moderate cognitive impairment and fatigue. Alixorexton was generally safe and well tolerated across all doses tested in the LTE. No serious TEAEs were reported. Most TEAEs were mild to moderate in severity. The most common TEAEs in the LTE were insomnia, headache, pollakiuria, and upper respiratory tract infection. Alixorexton is currently being evaluated in the phase 3 Brilliance Studies in adults with NT1 and NT2, and in the phase 2 Vibrance-3 study in adults with IH (Brilliance NT1 – Study 302: NCT07455383; Brilliance NT2 – Study 303: NCT07502443; Brilliance NT1 – Study 304: NCT07540897; Vibrance-3: NCT06843590). Alixorexton (formerly referred to as ALKS 2680) is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH). Orexin, a neuropeptide produced in the lateral hypothalamus, is considered to be the master regulator of wakefulness due to its activation of multiple, downstream wake-promoting pathways that project widely throughout the brain. Targeting the orexin system may address excessive daytime sleepiness across hypersomnolence disorders, whether or not deficient orexin signaling is the underlying cause of disease. Alixorexton is currently being evaluated in the phase 3 Brilliance Studies in patients with NT1 and NT2, and in the phase 2 Vibrance-3 study in patients with IH. The U.S. Food and Drug Administration (FDA) has granted alixorexton Breakthrough Therapy designation for the treatment of NT1 and Orphan Drug Designation (ODD) for the treatment of IH. The European Commission has granted ODD to alixorexton for the treatment of narcolepsy.

Biotechs Tillväxt i branschen	-14.59%
Intäkternas tillväxttakt	8.31%
Avkastning på eget kapital	8.72%
Nettomarginal	9.78%
Senaste uppdateringen av resultatet	31 Mar 2026

Datum	Intäkter	Intäkter	G+A Kostnader	FoU-kostnader
31 Mar 26	1,562	153	773	342
31 Dec 25	1,476	242	715	311
30 Sep 25	1,521	338	674	277
30 Jun 25	1,505	348	652	255
31 Mar 25	1,514	356	648	238
31 Dec 24	1,558	372	656	234
30 Sep 24	1,505	387	679	250
30 Jun 24	1,508	386	686	254
31 Mar 24	1,726	570	714	262
31 Dec 23	1,663	519	702	259
30 Sep 23	1,591	455	671	172
30 Jun 23	1,462	300	669	206
31 Mar 23	1,121	-9	625	229
31 Dec 22	1,112	-33	603	260
30 Sep 22	1,132	-129	627	370
30 Jun 22	1,173	-94	610	387
31 Mar 22	1,201	-62	600	391
31 Dec 21	1,174	76	550	291
30 Sep 21	1,129	-92	566	401
30 Jun 21	1,100	-63	558	376
31 Mar 21	1,044	-95	551	373
31 Dec 20	1,039	-111	539	395
30 Sep 20	1,171	-74	566	462
30 Jun 20	1,162	-126	585	477
31 Mar 20	1,194	-139	606	489
31 Dec 19	1,171	-197	599	513
30 Sep 19	1,074	-201	598	412
30 Jun 19	1,067	-183	578	406
31 Mar 19	1,092	-173	561	409
31 Dec 18	1,094	-139	537	415
30 Sep 18	1,054	-139	507	410
30 Jun 18	1,023	-141	477	414
31 Mar 18	937	-152	448	406
31 Dec 17	903	-158	422	413
30 Sep 17	842	-169	417	389
30 Jun 17	804	-196	408	384
31 Mar 17	781	-200	395	382
31 Dec 16	746	-208	383	378
30 Sep 16	695	-257	373	382
30 Jun 16	668	-275	372	376
31 Mar 16	624	-274	347	367
31 Dec 15	628	-227	320	336
30 Sep 15	640	-127	287	317

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/07/14 14:45
Aktiekurs vid dagens slut	2026/07/09 00:00
Intäkter	2026/03/31
Årlig intjäning	2025/12/31

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

Analytiker	Institution
null null	Baird
Joel Beatty	Baird
Luke Herrmann	Baird

Alkermes Tidigare resultatutveckling

Tidigare kriterier kontrolleras 2/6

Viktig information

Senaste uppdateringar av tidigare prestationer

Recent updates

Alkermes Announces Interim Results From Long-Term Extension Study Of Alixorexton In Adults With Narcolepsy Type 1 And Type 2

Insufficient new directors

Fördelning av intäkter och kostnader

Resultat- och intäktshistorik

Fritt kassaflöde vs resultatanalys

Analys av tidigare vinsttillväxt

Avkastning på eget kapital

Avkastning på tillgångar

Avkastning på sysselsatt kapital

Upptäck starka bolag som tidigare presterat bra

Företagsanalys och finansiella data Status

Datakällor

Analysmodell och snöflinga

Industri- och sektormått

Källor för analytiker